Immix Biopharma (Nasdaq: IMMX)
Biotechnology ResearchCalifornia, United States11-50 Employees
Immix Biopharma is a clinical-stage biotechnology company focused on developing cell therapies for AL amyloidosis and other autoimmune diseases. Its lead program, NXC-201, is a next-generation CAR-T therapy that has FDA IND clearance and is under evaluation in the NEXICART-1 Phase 1b/2 trial that began in 2021. The program is described as potentially enabling rapid resolution of cytokine release syndrome, with a median onset around day 1 and a median duration of one day. NXC-201 has received orphan designation from the FDA in AL amyloidosis and in multiple myeloma, and from the EMA in AL amyloidosis. The company is based in Los Angeles, California, operating in the biotechnology research industry with a relatively small team. In March 2026, Immix announced the appointment of Richard Graydon, MD, PhD, as Chief Medical Officer, effective July 1, 2026.
1-888-653-2347 
support@leadiq.com 
